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Summary
Background Neonatal interventions are largely focused on reduction of mortality and progression towards Millennium 
Development Goal 4 (child survival). However, little is known about the global burden of long-term consequences of 
intrauterine and neonatal insults. We did a systematic review to estimate risks of long-term neurocognitive and other 
sequelae after intrauterine and neonatal insults, especially in low-income and middle-income countries.
Methods We searched Medline, Cumulative Index to Nursing and Allied Health Literature, the Cochrane Library, and 
Embase for studies published between Jan 1, 1966, and June 30, 2011, that reported neurodevelopmental sequelae 
after preterm or neonatal insult. For unpublished studies and grey literature, we searched Dissertation Abstracts 
Inter national and the WHO library. We reviewed publications that had data for long-term outcome after deﬁ ned 
neonatal insults. We summarised the results with medians and IQRs, and calculated the risk of at least one sequela 
after insult.
Findings Of 28 212 studies identiﬁ ed by our search, 153 studies were suitable for inclusion, documenting 22 161 survivors 
of intrauterine or neonatal insults. The overall median risk of at least one sequela in any domain was 39·4% 
(IQR 20·0–54·8), with a risk of at least one severe impairment in any insult domain of 18·5% (7·7–33·3), of at least 
one moderate impairment of 5·0% (0·0–13·3%), and of at least one mild impairment of 10·0% (1·4–17·9%). The 
pooled risk estimate of at least one sequela (weighted mean) associated with one or more of the insults studied 
(excluding HIV) was 37·0% (95% CI 27·0–48·0%) and this risk was not signiﬁ cantly aﬀ ected by region, duration of 
the follow-up, study design, or period of data collection. The most common sequelae were learning diﬃ  culties, 
cognition, or develop mental delay (n=4032; 59%); cerebral palsy (n=1472; 21%); hearing impairment (n=1340; 20%); 
and visual impairment (n=1228; 18%). Only 40 (26%) studies included data for multidomain impairments. These 
studies included 2815 individuals, of whom 1048 (37%) had impairments, with 334 (32%) having multiple 
impairments.
Interpretation Intrauterine and neonatal insults have a high risk of causing substantial long-term neurological 
morbidity. Comparable cohort studies in resource-poor regions should be done to properly assess the burden of these 
conditions, and long-term outcomes, such as chronic disease, and to inform policy and programme investments.
Funding The Bill & Melinda Gates Foundation, Saving Newborn Lives, and the Wellcome Trust.
Introduction
Nearly 140 million children per year are born worldwide, 
with 3·6 million neonatal deaths and 2·6 million 
stillbirths.1–3 More than 90% of neonatal deaths occur in 
resource-poor countries, mostly in rural areas.4 
Worldwide, an increasing proportion (currently more 
than 40%) of mortality in children younger than 5 years 
occurs in the neonatal period (aged 0–28 days), which 
has led to increased attention to neonatal mortality. The 
common causes of neonatal mortality include preterm 
birth complications, intrapartum-related factors such as 
hypoxic ischaemic encephalopathy, infections (notably 
sepsis, meningitis, and neonatal tetanus), and other 
conditions such as jaundice and congenital infections 
(cytomegalovirus, toxoplasma, syphilis, and rubella).4–6 
However, the prevalences of these insults and the long-
term consequences for neonates who survive, particularly 
in resource-poor regions, are unclear.4
Many neonates survive major insults without any 
evidence of impairment because of the plasticity of the 
developing brain and improvements in medical care. 
However, in some newborn babies, insults can cause 
varying degrees of long-term neurodevelopmental 
impairment.5–8 These impairments cause a major socio-
economic burden, especially in resource-poor countries. 
Intrauterine and neonatal insults substantially aﬀ ect the 
global burden of disease, measured in disability-adjusted 
life-years, because they contribute to both premature 
mortality and long-term disability.9 However, little is 
known about the severity and distribution of long-term 
impairments after intrauterine or neonatal insults. As a 
result, sequelae from intrauterine and neonatal insults 
have not been adequately captured in estimates of the 
global burden of disease.10
We reviewed published data for the long-term 
consequences of intrauterine and neonatal insults. The 
questions addressed were: what are the long-term 
outcomes after intrauterine and neonatal insults 
(neonatal sepsis, neonatal meningitis, hypoxic 
ischaemic neonatal encephalopathy, neonatal jaundice, 
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preterm birth, neonatal tetanus, congenital infections 
[cytomegalovirus, toxoplasma, syphilis, rubella], and 
HIV)? What is the risk and severity of at least one 
sequela and of multiple sequelae reported after these 
insults? And what is the risk and severity of sequelae 
after multiple insults for one infant?
Methods
Search strategy and selection criteria
We included studies that reported neurological outcomes 
after an identiﬁ able and well deﬁ ned neonatal insult 
(webappendix). We searched Medline, Cumulative Index 
to Nursing and Allied Health Literature, the Cochrane 
Library, and Embase for studies published between Jan 1, 
1966, and June 30, 2011. For unpublished studies and 
grey literature, we searched Dissertation Abstracts 
International and WHO library. The initial search 
strategy used the words “neonate” and “outcome”, and 
each of the exposures (eg, “jaundice”) listed in 
webappendix pp 6–7. These searches were reﬁ ned by the 
addition of terms such as  “complications” or “diagnosis” 
(webappendix p 7). Further searches were done by 
replacement of “outcome” with “sequela”, which were 
then reﬁ ned by addition of speciﬁ c outcomes, for 
example, “neurological impairment” (webappendix 8–9). 
The reference list of all identiﬁ ed reports and articles 
were manually searched for additional studies. No 
language restrictions were used.
We reviewed the online abstracts of studies identiﬁ ed 
in the database searches and obtained reprints of 
potentially eligible studies. Disagreements about 
eligibility were resolved by discussion in a ﬁ nal review 
with CRJCN. Inclusion criteria were: occurrence of the 
insult during the intrauterine or neonatal period (up to 
28 days of life); insults were veriﬁ ed with the appropriate 
diagnostic method or criteria (webappendix); follow-up 
of at least 6 months after the neonatal insult to exclude 
transient impairments and capture sequelae that become 
evident later (eg, epilepsy); use of standardised tests or 
controls in neurodevelopmental assessment; at least 
80% of neonates surviving the insult identiﬁ ed for 
follow-up for at least the ﬁ rst 6 months; and study 
publication between Jan 1, 1966, and June 30, 2011 
inclusive. We excluded case series, single case reports, 
and reviews.
Data extraction
Two reviewers (MKM and MA) examined the titles, 
abstracts, and studies independently with identical case 
deﬁ nitions and study selection criteria (webappendix). 
Data were organised into broad domains for each insult: 
learning diﬃ  culties, cognition or developmental delay; 
seizures, convulsion, or epilepsy; behavioural problems; 
cerebral palsy; and hearing and vision. Additionally, a 
category for gross motor and coordination disorders was 
included to capture data from studies that did not 
explicitly identify cerebral palsy but reported gross motor 
function or coordination diﬃ  culties. When a single study 
described multiple insults, data from the various insults 
were extracted separately.
To assess the severity of the reported sequelae, we used 
the deﬁ nitions of severity of sequelae from the Global 
Burden of Disease, Disease Control Priorities Project.9 
We developed a table to include commonly reported mild 
See Online for webappendix
Mild Moderate Severe 
Cognition Cognitive Z score <–1 for more than one 
test, or mean Z score <–1 for a 
construction task and non-verbal task, or 
mean Z score <–1 for verbal tasks 
Cognitive Z score <–2 for more than one test, or mean 
Z score <–2 for a construction task and non-verbal task, 
or mean Z score <–2 for verbal tasks
Z score <–3 for more than one severe 
test, or mean Z score <–3, or mean 
Z score <–3 for verbal tasks
Motor Diﬃ  culty in everyday motor activities 
appropriate for age but able to move 
around without help
Diﬃ  culty in holding implements, dressing, and sitting 
upright. Able to move around with help
Inability to walk and absence of 
functional use of hands
Hearing Audiometric hearing threshold level of 
26–30 dB HL in children aged <15 years 
and 26–40 dB HL in adults
Audiometric hearing threshold level of 31–60 dB HL in 
children aged <15 years and 41–60 dB HL in adults. 
Hearing aid not normally used. Or, audiometric hearing 
threshold level of 31–60 dB HL in children aged <15 years 
and 41–60 dB HL in adults. Hearing aid normally used
Audiometric hearing threshold level 
of 61 dB HL or greater. Hearing aid 
not normally used. Or, audiometric 
hearing threshold level of 61 dB HL or 
greater. Hearing aid normally used
Vision Visual acuity in the best eye of <6/12 but 
≥6/18, or corresponding visual ﬁ eld loss
Visual acuity in the best eye of <6/18 but ≥6/60; 
or, corresponding visual ﬁ eld loss
Visual acuity in the best eye of <6/60 
but >3/60; or, visual ﬁ eld loss with 
blindness (visual acuity in the best eye 
of <3/60); or, corresponding visual 
ﬁ eld loss
Seizure disorder More than one non-febrile seizure 
per year
More than one non-febrile seizure per month More than one non-febrile seizure 
per week
Behavioural* Any reported ·· ··
Multidomain One or two domains mildly aﬀ ected Three or more domains mildly aﬀ ected, or one 
moderately aﬀ ected and more than one mildly aﬀ ected
If any domain is severely aﬀ ected, or 
two or more are moderately aﬀ ected
HL=hearing level. *Deﬁ nitions of behavioural problems could not be standardised or assessed. 
Table 1: Grading of severity of impairment across multiple domains
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to moderate impairments. To do so, we took into account 
the functional range when a standardised test was 
applied, and the degree of diﬃ  culty in doing routine age-
appropriate self-care and motor activities (table 1).
Statistical analysis
We summarised the results by calculation of the medians 
and IQRs of the proportions of individual with any sequela 
resulting from each insult independently and overall. 
Similarly, we recorded the proportions of impairments 
that were severe, moderate, or mild. Most of the studies 
reported the number of patients for each impaired domain 
separately (eg, number or percentage with hearing loss), 
omitting to systematically assess all domains and describe 
those with multiple impairments. Thus, we could not 
easily derive mutually exclusive categories for each domain 
(eg, cerebral palsy only, or learning diﬃ  culties only); 
therefore some overlap was unavoidable.
To investigate the eﬀ ect of covariates (WHO region, 
period of data collection, study design [prospective or 
retrospective], and duration of follow-up after discharge 
from hospital) on the risk of at least one sequel, each 
covariate was categorised into subgroups. We did a 
random eﬀ ect meta-analysis of all available studies in 
each subgroup to calculate estimates of risk for each 
covariate—eg, for duration of follow-up we calculated 
estimates for less than 12 months, 12–35 months, 
36–60 months, and more than 60 months. We examined 
each covariate ﬁ tted singly and compared estimates with 
the most prevalent subgroup by number of survivors 
followed up and assessed (bivariate meta-regression). 
Finally, we included all the four covariates in a 
multivariable meta-regression analysis. We calculated 
heterogeneity with I².11 All analyses were done with Stata 
(version 11.0).
Role of the funding source
The sponsors of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Our search identiﬁ ed 28 212 publications. From the titles 
we selected 1330 (5%) for review of the abstract and ﬁ nally 
selected 949 studies for detailed review (ﬁ gure 1). We 
excluded 796 (84%) after assessment of full text because 
they did not meet the inclusion criteria. The main reasons 
for exclusion were that numbers of survivors with 
sequelae could not be extracted; no clear description or 
diagnosis of the neonatal insult was provided; less than 
80% of survivors were followed up after deﬁ nite exposure 
in the ﬁ rst 6 months; and no appropriate test to establish 
the nature and extent of the sequelae or impairment was 
done (ﬁ gure 1). Additional reports were excluded because 
they were reviews, case series, or commentaries.
We were unable to identify any unpublished data that 
met our inclusion criteria. 153 studies were included 
(ﬁ gure 1). 49 (32%) presented data for preterm birth, 
28 (18%) for hypoxic ischaemic encephalopathy, 21 (14%) 
for neonatal jaundice, ten (6%) for meningitis, and ﬁ ve 
(3%) for sepsis. Five studies presented data for more 
than one insult. 68 papers (44%) were from the Americas 
(65 from North America and three from South America), 
59 from Europe, 15 from the western Paciﬁ c, ﬁ ve from 
southeast Asia, three from Africa, and one from the 
eastern Mediterranean. Two studies covered several 
regions. The webappendix shows the references of 
these studies.
Table 2 summarises the prevalence of each impair-
ment per insult and overall. 22 161 (82%) of the survivors 
(excluding those with HIV) were followed up and 
assessed. The median number of survivors per study 
was 50 (IQR 24–113). The median percentage loss to 
follow-up was 8·1% (0·0–23·9). 6851 (31%) of survivors 
assessed had an impairment. The most common 
impairments were learning diﬃ  culties, cognition, or 
developmental delay (n=4032; 59%); cerebral palsy 
(1472; 21%); hearing impairment (1340; 20%); and visual 
impairment (1228; 18%). Behavioural problems were 
28 212 papers identified by search
1330 selected for review of abstracts
26 682 excluded, titles not relevant
381 excluded, abstracts not relevant
796 excluded
265 because numbers with sequelae not included or not extractable
226 neonatal insult not diagnosed and described
128 because <80% of survivors followed up after definite exposure
within the first 6 months
44 did not test nature and extent of sequelae or impairment appropriately
133 reviews, case series, or commentaries
153 papers analysed*
5 sepsis
28 hypoxic ischaemic encephalopathy
10 meningitis
49 preterm
21 jaundice
4 tetanus
19 cytomegalovirus
9 herpes
6 rubella
6 toxoplasma
2 HIV
0 syphilis
949 selected for full text review
Figure 1: Literature review
*Six studies included data for more than one insult.
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reported in 718 patients (11%, IQR 5–25; table 3). The 
overall median risk of at least one sequela in any 
domain was 39·4% (IQR 20·0–54·8), with a risk of at 
least one severe impairment in any one domain of 
18·5% (7·7–33·3), at least one moderate impairment of 
5·0% (0·0–13·3), and at least one mild impairment of 
10·0% (1·4–17·9).
In nine studies most infants had more than one insult. 
Most (2405; 98%) survivors who had sepsis were born 
prematurely. For survivors with preterm birth as the 
only insult, quantiﬁ cation of the degree of impairment 
by gestational age at birth was a challenge because of 
overlapping gestations in the studies. 13 studies 
speciﬁ cally examined newborn babies who weighed 
1500 kg or less. The risk of at least one sequela in this 
subgroup was 26·7% (23·9–44·4). The concentration of 
total serum bilirubin can aﬀ ect the likelihood of brain 
impairment. Therefore, we separately analysed data 
from studies of neonates who had bilirubin 
concentrations of ≥400 μmol/L or more. 395 neonates 
were followed up, and 117 (30%) had impairments. The 
most common impairments were gross motor (n=72, 
62%) and sensorineural hearing loss (n=23, 20%). The 
overall risk of impairments in this subgroup was 26·9% 
(IQR 16·7–61·5), with 18·0% (3·1–33·3) having severe 
impairments. 505 preterm neonates had hyper-
bilirubinaemia, of whom 488 (97%) were followed up 
and assessed, and 140 (28%) had impairments. Of those 
impaired, 60 (43%) had learning diﬃ  culties, 39 (28%) 
cerebral palsy, and 33 (24%) sensorineural hearing loss 
(eight had mixed impairments). The median risk of at 
least one sequela in any domain in preterm newborns 
with hyperbilirubinaemia was 29·4% (IQR 27·3–45·0).
Only 40 (26%) studies presented data for multi domain 
impairments. These studies included 2815 individuals, of 
whom 1048 (37%) had impairments, with 334 (32%) 
having multiple impairments. In those with multiple 
impairments, 175 (52%) had three or more sequelae, all 
with cerebral palsy and learning diﬃ  culties plus a third or 
fourth impaired domain such as vision or hearing. 
64 (19%) patients had a combination of cerebral palsy 
plus learning diﬃ  culties only, whereas 34 (10%) had 
cerebral palsy plus epilepsy. Learning diﬃ  culties 
or cerebral palsy in combination with another impaired 
domain (excluding each other or epilepsy) was docu-
mented in 39 (12%) patients.
Two studies documented HIV infection during the 
neonatal period.12,13 36 neonates were infected before the 
end of the neonatal period, of whom 15 (42%) had 
learning diﬃ  culties compared with 13 of 56 (23%) of 
those infected after the neonatal period. We excluded 
HIV from the ﬁ nal pooled estimate because of the small 
sample sizes in the two studies. 
The pooled risk estimate of development of at least 
one sequela (weighted mean) in any domain for all 
insults (excluding HIV) was 37·0% (95% CI 27·0–48·0). 
The risk was highest after rubella infection, and lowest 
for survivors of neonatal jaundice; ﬁ gure 2). 
Overall, heterogeneity was high between the studies 
used to estimate the risk of at least one sequela 
irrespective of the type of insult (ﬁ gure 2). However, the 
risks did not diﬀ er with any of the four covariates tested: 
WHO region, period of data collection, duration of 
follow-up, and study design (prospective or retrospective; 
table 4). Other covariates—eg, socioeconomic status—
were rarely reported.
Neonates 
assessed (n)
Sequelae (n; %) Type of sequelae (n; % of total with impairment)
Cognition, general 
developmental 
delay, or learning 
diﬃ  culties
Cerebral palsy Deaf or 
hearing loss
Impaired 
vision or blind
Gross motor and 
coordination*
Epilepsy Behavioural 
problems
Sepsis (5 studies) 2442 977 (40%) 720 (74%) 353 (36%) 97 (10%) 317 (32%) 5 (1%) ·· ··
Meningitis (11 studies) 501 209 (42%) 209 (100%) 43 (21%) 25 (12%) 84 (40%) 10 (5%) 24 (11%) 3 (1%)
Hypoxic ischaemic 
encephalopathy (27 studies)
2708 1002 (37%) 453 (45%) 291 (29%) 95 (9%) 258 (26%) 167 (17%) 122 (12%) 15 (1%)
Preterm birth (47 studies) 6558 2006 (31%) 1209 (60%) 539 (27%) 148 (7%) 224 (11%) 202 (10%) 20 (1%) 25 (1%)
Jaundice (20 studies) 7212 1311 (18%) 985 (75%) 190 (14%) 146 (11%) ·· 36 (3%) 40 (3%) 57 (4%)
Tetanus (4 studies) 109 28 (26%) 28 (100%) 1 (4%) ·· ·· 4 (14%) ·· 6 (21%)
Cytomegalovirus (17 studies) 918 377 (41%) 250 (66%) 23 (6%) 251 (67%) 13 (3%) 60 (16%) 23 (6%) 7 (2%)
Herpes (9 studies) 311 116 (37%) 109 (94%) 32 (28%) 2 (2%) 55 (47%) 34 (29%) 27 (23%) 2 (2%)
Rubella (6 studies) 890 720 (81%) 42 (6%) ·· 576 (80%) 191 (27%) 44 (6%) ·· 2 (<1%)
Toxoplasmosis (5 studies) 512 105 (21%) 27 (26%) ·· ·· 86 (82%) 1 (1%) 12 (11%) ··
Syphilis (0 studies) ·· ·· ·· ·· ·· ·· ·· ·· ··
Overall 22 161 6851 (31%) 4032 (59%) 1472 (21%) 1340 (20%) 1228 (18%) 563 (8%) 268 (4%) 117 (2%)
Impairment by sequelae type greater than 100% because of overlap. *Cerebral palsy was not deﬁ ned and classiﬁ ed but motor and coordination impairments were reported. 
Table 2: Summary of sequelae risk after intrauterine and neonatal insults
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Discussion
In our study, the median overall risk of sequelae in 
survivors of intrauterine and neonatal insults was very 
high. Our Article provides supportive evidence that 
intrauterine and neonatal insults result in signiﬁ cant 
long-term neurological morbidity and that these insults 
have a high risk of aﬀ ecting more than one domain (eg, 
cognitive impairment, motor impairment and hearing 
and vision loss). Despite the fact that we initially identiﬁ ed 
many studies, few had data that were suitable for analysis, 
which is common in reviews of global estimates. For 
example, in a series of reviews of child mortality data,14 
only 308 studies were included from more than 
17 000 abstracts. Data for morbidity and impairment are 
even worse, which is indicative of the low value placed on 
the collection of disability data.
Overall Sepsis Meningitis Hypoxic 
ischaemic 
encephal-
opathy
Preterm 
birth
Jaundice Tetanus Cytomegalo-
virus
Herpes Rubella Toxoplas-
mosis
At least one sequela in any 
domain
39·4% 
(20·0–54·8)
48·9% 
(39·1–59·2)
46·4% 
(36·9–68·4)
44·2% 
(20·6–53·9)
27·9% 
(18·6–46·4)
25·3% 
(13·2–39·2)
20·8% 
(11·5–45·0)
48·3% 
(20·8–73·8)
51·5% 
(31·3–56·5)
82·0% 
(68·5–100·0)
55·6% 
(51·2–85·7)
Cognitive or learning 
diﬃ  culties or developmental 
delay
26·0% 
(14·3–43·4)
30·0% 
(26·4–44·4)
33·3% 
(26·7–36·8)
29·7% 
(13·0–40·7)
20·9% 
(12·5–39·5)
16·1% 
(11·7–23·9)
20·8% 
(10·5–95·8)
27·8% 
(9·5–57·1)
12·5% 
(5·2–17·4)
22·7% 
(7·1–23·6)
33·3% 
(19·1–70·8)
Cerebral palsy 15·5% 
(9·2–28·6)
12·4% 
(11·1–14·9)
11·7% 
(6·2–29·0)
28·3% 
(19·1–42·0)
11·6% 
(8·0–17·7)
10·5% 
(3·7–14·4)
·· 24·3% 
(11·4–35·8)
29·9% 
(20·0–39·1)
·· ··
Hearing loss 13·4% 
(5·0–28·6)
18·7% 
(8·9–36·1)
8·6% 
(2·6–13·1)
10·0% 
(5·0–11·6)
2·9% 
(1·2–8·7)
11·1% 
(5·7–23·0)
·· 25·0% 
(16·1–50·0)
·· 56·9% 
(28·6–69·9)
··
Visual disturbance 12·9% 
(3·5–33·4)
12·5% 
(11·1–21·9)
20·0% 
(13·3–36·8)
12·0% 
(3·3–24·3)
2·8% 
(1·4–11·3)
·· ·· 7·1% 
(2·3–21·8)
48·7% 
(40·8–57·2)
37·3% 
(31·3–65·2)
55·6% 
(51·2–85·7)
Epilepsy 14·7% 
(7·2–44·4)
·· 15·8% 
(5·4–50·0)
10·9% 
(3·4–23·1)
31·3% 
(29·4–33·3)
11·9% 
(3·5–16·7)
·· 11·1% 
(10·7–21·7)
32·5% 
(30·2–36·1)
·· 14·3% 
(11·1–16·7)
Gross motor and coordination 
problems*
16·9% 
(10·0–29·2)
·· 6·7% 
(2·6–10·6)
20·1% 
(5·6–33·3)
18·9% 
(11·8–25·6)
20·1% 
(12·8–39·4)
·· 10·9% 
(2·2–58·2)
25·0% 
(22·2–37·5)
·· 6·6% 
(4·8–8·3)
Behavioural problems 10·7% 
(5·5–25·0)
·· ·· 13·1% 
(2·9–23·3)
9·4% 
(4·9–17·9)
·· ·· ·· ·· ·· ··
Severe sequela in at least one 
domain
18·5% 
(7·7–33·3)
39·9% 
(32·1–44·8)
15·0% 
(10·8–26·3)
27·1% 
(20·6–38·5)
9·6% 
(6·6–18·2)
9·3% 
(2·3–22·7)
·· 11·1% 
(5·6–27·3)
34·8% 
(25·0–40·6)
82·3% 
(63·6–96·1)
22·2% 
(3·2–25·0)
Moderate sequelae in at least 
one domain
5·0% 
(0·0–13·3)
9·3% 
(0·0–21·8)
6·7% 
(1·1–13·3)
2·9% 
(0·0–8·3)
5·5% 
(0·0–13·4)
1·5% 
(0·0–12·7)
·· 11·1% 
(0·0–27·3)
5·8% 
(0·0–12·5)
·· 22·8% 
(2·1–29·2)
Minor or mild sequelae in at 
least one domain
10·0% 
(1·4–17·9)
·· 10·0% 
(0·0–20·0)
8·5% 
(1·4–12·5)
13·9% 
(4·7–25·0)
4·2% 
(2·6–10·9)
·· 11·1% 
(8·0–19·1)
12·5% 
(5·2–17·4)
13·1% 
(4·1–31·7)
11·1% 
(5·0–37·5)
Severe cognitive or learning 
diﬃ  culties
17·3% 
(6·3–26·9)
26·4% 
(22·2–30·0)
11·4% 
(5·6–18·9)
25·0% 
(17·9–40·7)
7·0% 
(4·1–18·7)
·· ·· 19·6% 
(5·9–37·8)
36·4% 
(6·3–40·6)
·· 10·7% 
(4·8–16·7)
Moderate cognitive or learning 
diﬃ  culties
7·1% 
(0·0–12·5)
·· ·· 6·9% 
(0·0–11·5)
11·0% 
(5·6–13·9)
·· ·· ·· 7·5% 
(4·3–10·0)
·· 6·5% 
(4·8–8·3)
Mild cognitive or learning 
diﬃ  culties
10·0% 
(0·7–15·0)
·· 14·4% 
(0·0–15·8)
2·4% 
(0·0–10·0)
14·0% 
(7·4–22·7)
·· ·· 13·2% 
(3·6–14·3)
9·1% 
(3·0–15·0)
·· 8·9% 
(8·3–9·5)
Severe cerebral palsy 11·4% 
(7·4–24·0)
·· 10·0% 
(2·7–11·4)
24·0% 
(16·7–36·5)
9·2% 
(4·1–12·1)
·· ·· ·· ·· ·· ··
Moderate cerebral palsy 2·4% 
(0·0–6·6)
·· ·· 1·4% 
(0·0–4·3)
5·5% 
(3·5–7·5)
·· ·· ·· ·· ·· ··
Mild cerebral palsy 1·5% 
(0·0–4·1)
·· 1·8% 
(0·0–12·8)
0·9% 
(0·0–1·6)
4·1% 
(2·0–6·7)
·· ·· ·· ·· ·· ··
Deaf or severe hearing loss 4·9% 
(1·1–17·4)
11·1% 
(4·1–19·4)
0·6% 
(0·0–1·5)
·· 1·8% 
(0·9–4·3)
·· ·· 9·5% 
(5·6–17·4)
·· 37·7% 
(21·4–60·2)
··
Mild to moderate hearing loss 10·4% 
(0·0–15·2)
4·8% 
(0·0–21·4)
6·5% 
(0·9–13·1)
·· 0·3% 
(0–4·3)
·· ·· 13·6% 
(11·1–16·7)
·· 13·1% 
(5·4–17·9)
··
Blind or severe visual loss 2·4% 
(0·6–10·0)
11·1% 
(5·6–12·5)
4·5% 
(1·1–12·3)
·· 1·9% 
(0·5–2·8)
·· ·· ·· ·· ·· 22·2% 
(3·2–25·0)
Mild to moderate visual 
impairment
·· ·· 14·5% 
(4·5–30·0)
·· 0·7% 
(0·0–4·0)
·· ·· ·· ·· ·· 33·3% 
(7·1–66·7)
Multiple impairments 13·8% 
(8·0–33·3)
·· ·· 20·5% 
(14·7–37·8)
8·1% 
(3·7–10·2)
12·4% 
(5·5–19·4)
·· 22·6% 
(8·3–33·3)
·· ·· ··
Data are median (IQR). No data are given when the numbers were too few, domain was not assessed, or the impairment was graded. *Cerebral palsy was not deﬁ ned and classiﬁ ed but motor and coordination 
impairments were reported.
Table 3: The risk of impairment sequelae by insult and overall
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Although we recorded signiﬁ cant heterogeneity, the 
decade in which data were collected did not signiﬁ cantly 
aﬀ ect the risk of development of sequelae, which suggests 
that the risk of long-term impairment after intrauterine 
and neonatal insults has not changed over time. 
Alternatively, advances in technologies for care of sick 
newborn babies might have increased survival in 
neonates who would have otherwise died, with the 
increased proportions of impairments in this group of 
survivors cancelling out any reduction in impairments 
gained in less severely aﬄ  icted newborn babies. Large 
cohort studies in a range of health-care settings but with 
consistent deﬁ nitions of exposure, outcome, mortality, 
and sequelae are needed to advance understanding of 
this issue. Most of the studies were from Europe or North 
America, where the standard of care diﬀ ers greatly to that 
in low-income settings. The predominance of studies 
from only two regions might be why WHO region did 
not aﬀ ect the risk of development of sequelae. However, 
combination of studies of diﬀ erent insults and with 
varying outcomes could be an important contributor to 
the recorded heterogeneity.
We did not identify any acceptable studies of syphilis. 
Although long-term eﬀ ects of maternal syphilis are well 
known,15 liberal use of penicillin both in the antenatal 
period and as treatment for neonatal sepsis might have 
substantially reduced this burden. Tetanus was estimated 
to cause only about 60 000 neonatal deaths in 2009, 
a dramatic reduction from the previous decade.16–19 
However, the data we extracted for impairments after 
neonatal tetanus are not robust because of the few studies 
that were acceptable and low numbers of patients. The 
very high inpatient and immediate mortality after 
discharge20–22 of tetanus might limit the number of 
suitable studies. However, the focus might have been on 
neonatal deaths, and the impairment burden of this 
disorder has been poorly assessed.
Vertical HIV transmission is a substantial burden:23 4% 
or more of pregnant women were infected in the studies 
that we identiﬁ ed. 24–27 With the expansion of antiretroviral 
treatment for children in many countries, including 
those in resource-poor regions,28,29 many HIV-infected 
neonates survive into adulthood. Importantly, the timing 
of HIV infection is thought to be one of the factors that 
aﬀ ects long-term neurological and developmental 
outcome.30–32 Despite this scenario, only two studies met 
our criteria and documented the timing of HIV infection 
in the neonatal period and long-term sequelae.12,13 
Although these two studies had small sample sizes they 
do indicate that HIV infection in the intrauterine or early 
neonatal period might be associated with a worse long-
term neurological outcome than later HIV infections. 
More studies with larger follow-up cohorts are required 
to further understand the eﬀ ect of HIV on long-term 
neurological outcomes.
Neonates commonly present with multiple insults. 
Because the median impairment after preterm birth 
alone was 28%, and that of septic premature neonates 
was 49%, sepsis probably increases the likelihood of 
neurological impairment in preterm neonates. Moreover, 
the degree of impairment was more likely to be severe in 
septic preterm neonates than in nonseptic neonates. 
However, because the studies of sepsis that we identiﬁ ed 
were mostly of premature neonates, the sequelae 
resulting from septicaemia in term newborn babies are 
still unclear and few studies exist about the outcome of 
0·40 (0·38–0·42)
0·42 (0·37–0·46)
0·37 (0·35–0·39)
0·31 (0·29–0·32)
0·18 (0·17–0·19)
0·26 (0·18–0·35)
0·41 (0·38–0·44)
0·37 (0·32–0·43)
0·81 (0·78–0·83)
0·21 (0·17–0·24)
0·37 (0·27–0·48)
Sepsis
Meningitis
Hypoxic ischaemic encephalopathy
Preterm
Jaundice
Tetanus
Cytomegalovirus
Herpes
Rubella
Toxoplasmosis
Overall (p<0·0001)
0 0·834
Weighted mean (95% CI)
Figure 2: Random eﬀ ect meta-analysis of the risk of development of one sequela by insult
Participants 
(number of 
studies)
Bivariate 
meta-regression*
Multivariate 
meta-regression† 
OR (95% CI) p value OR (95% CI) p value
WHO region
Americas 13 951 (68) 1·00 ·· 1·00 ··
European 6716 (59) 1·03 (0·92–1·16) 0·58 0·93 (0·67–1·30) 0·68
Western Paciﬁ c 1187 (15) 0·97 (0·85–1·12) 0·72 0·86 (0·61–1·21) 0·38
Southeast Asia 158 (5) 0·90 (0·71–1·14) 0·36 0·78 (0·52–1·18) 0·24
Africa 115 (3) 1·06 (0·80–1·39) 0·70 0·93 (0·61–1·41) 0·71
East Mediterranean 34 (1) 0·85 (0·53–1·35) 0·49 0·74 (0·42–1·29) 0·28
Data collection period (year)
<1980 7452 (38) 1·00 ·· 1·00 ··
1980–89 6559 (48) 0·94 (0·86–1·03) 0·18 0·87 (0·54–1·42) 0·59
1990–99 6108 (47) 1·09 (1·00–1·19) 0·06 0·97 (0·59–1·57) 0·89
≥2000 2042 (19) 0·94 (0·82–1·08) 0·37 0·86 (0·52–1·41) 0·55
Follow-up (months)
<12 1631 (29) 0·96 (0·86–1·06) 0·40 1·06 (0·90–1·24) 0·49
12–35 8184 (52) 1·01 (0·89–1·08) 0·85 1·07 (0·93–1·24) 0·33
36–60 1315 (18) 0·92 (0·88–1·06) 0·21 1·01 (0·87–1·18) 0·88
>60 10 002 (39) 1·00 ·· 1·00 ··
Mixed (across the age ranges) 1029 (15) 1·12 (1·01–1·33) 0·03 1·15 (0·96–1·38) 0·13
Study design
Prospective 20 095 (124) 1·00 ·· 1·00 ··
Retrospective 2066 (29) 1·06 (1·00–1·17) 0·28 1·05 (0·94–1·18) 0·39
*Estimates compared to most prevalent group within the subgroup. †Multivariate regression approach (WHO region 
with the Americas as the baseline, data collection period with <1980 as the baseline, follow-up with >60 months as 
the baseline). 
Table 4: Meta-regression analysis of the eﬀ ect of key variables on the risk of sequelae
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neonatal sepsis in term infants. The degree of 
impairment in preterm neonates with 
hyperbilirubinaemia did not diﬀ er from the background 
impairment due to preterm birth alone. Because jaundice 
in preterm births is very common,33,34 a proportion of 
neonates in the studies that had data only for long-term 
sequelae after preterm birth might also have developed 
hyperbilirubinaemia, hence the almost equal degree of 
impairment in the two groups.
Although early-onset brain damage, especially of the 
prefrontal cortex, could result in behavioural problems, 
assessment is very diﬃ  cult during the early years, 
especially when other severe impairments (eg, of motor 
and cognition) are present. At least a tenth of survivors 
have behavioural problems; however, in view of the 
above limitations, this proportion is likely to be an 
underestimate.
Our review has several limitations. First, nearly 20% 
of survivors were lost to follow-up. Loss to follow-up 
can bias results in two ways. Survivors with minor or 
no sequelae might be more prone to loss to follow-up 
because they perceive little beneﬁ t of being re-
examined.35 This eﬀ ect might skew the estimates 
towards more severe sequelae. However, emotional 
stress and stigma might also reduce follow-up and 
aﬀ ect the results.35,36 Additionally, those with severe 
impairments are likely to have a higher mortality than 
are those with mild to moderate sequelae during follow-
up.36 This eﬀ ect might leave survivors with spuriously 
low prevalences of impairment, or a preponderance of 
minor sequelae. Second, all the studies we reviewed 
were based in hospitals, which might not be a major 
constraint in high-income countries where access to 
care is almost universal, but in low-income countries 
might introduce a bias towards the inclusion of patients 
of relatively high social and economic status, who have 
better access to both acute and long-term health care 
and tend to have a lower risk of impairment.37 Third, we 
were able to extract data for multidomain impairments 
from only 25% of studies; thus, the number of multiple 
impairments might have been underestimated. 
Furthermore, data after multiple insults were sparse. 
Fourth, we used strict criteria, which excluded many 
studies, particularly those of preterm birth and HIV. 
Finally, our review shows the paucity of studies from 
resource-poor countries, especially sub-Saharan Africa, 
where only three studies met the inclusion criteria. 
Many factors make the situation and outcomes for 
neonates in low-income and middle-income countries 
very diﬀ erent to those in high-income settings: 
infections and intrapartum compli cations are more 
prevalent, many sick neonates do not present for care 
or present late to health-care facilities, inpatient 
treatment might not be optimum, and postdischarge 
care is often rudimentary.3,18,38 More than 98% of 
neonatal morbidity occurs in these countries1,3,38 and yet 
the least data are available. The absence of adequate 
data from these countries is the major constraint to 
understanding the burden of long-term impairments 
after neonatal insults, particularly in middle-income 
countries where neonatal care is increasing survival 
rates, but follow-up data lag behind the health-care 
systems.
Our Article has key implications for policy and research. 
First, in view of the poor outcome, prevention and 
improved treatment of complications during birth and in 
the neonatal period need to be emphasised, along with 
research into adjunct treatment approaches that might 
have neuroprotective eﬀ ects and that are feasible in low-
income settings. Second, more resources should be 
allocated for follow-up and rehabilitation of neonates 
who survive insults. Additionally, urgent attention is 
needed to improve multidomain, longer term assessment 
of these survivors.
Attention has only recently been given to worldwide 
newborn survival, and most eﬀ orts are directed at 
prevention of mortality. This focus is important in view 
of the short time to the Millennium Development Goals 
in 2015. However, insults during the intrauterine and 
neonatal period lead to substantial impairments, with 
major burdens on families and societies, and shortened 
life expectancy. Cohort studies, mainly from high-
income countries, show that exposures during 
pregnancy and birth are major risk factors for chronic 
disease. As neonatal care improves in middle-income 
and low-income countries, might we recreate the 
epidemics of impairment because of prematurity, such 
as retinopathy, seen in the mid-20th century in Europe 
and North America? We need better data to clarify 
this issue. 
Our results draw attention to the importance of both 
primary and secondary prevention measures. Many 
relevant insults such as intrapartum complications, 
neonatal tetanus, and neonatal jaundice can be 
prevented by timely and highly cost-eﬀ ective 
interventions. Compli cations of preterm birth can be 
reduced by cost-eﬀ ective interventions such as antenatal 
steroids, which are infrequently used in low-income and 
middle-income countries.39 Importantly, eﬀ ective care, 
including atten tion to appropriate use of oxygen, could 
reduce the severity of sequelae. Rehabilitation and 
supportive care might improve quality of life. However, 
changes to policy and programmes are unlikely without 
a more cohesive, interagency, proactive approach to 
improving data. 
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